ATAI Life Sciences

Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth

Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies

MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?

Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies

MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?

Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration

Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant

Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration

Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant

atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing

Atai Life Sciences: Capital Raise, Share Options, Cathie Wood And More On Biotech Psychedelics Leader

ATAI Life Sciences Recent News

ATAI Life Sciences Present A "New Recipe For Success" At The Psychedelic Capital Conference

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Sponsored

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results

National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000

The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics to study a non-hallucinogenic version of the psychedelic drug ibogaine.

New York's Horizons Psychedelic Conference Highlights Big Donations In The Growing Industry

Venture capitalist and businessman Stephen Jurvetson is joining an expanding group of prominent investors who are backing research into psychedelic ventures.

Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways

Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ: ATAI), a Peter Thiel-backed psychedelic startup that currently has 10 psychedelic programs in the works, has upped its stake in Compass Pat

This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop

Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O’Leary and

Psyched: MindMed and Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Gets Back To Trading

Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange.

Worthy Or Superfluous? Psychedelics Experts Discuss The Sector's Ongoing Patent Debate

Co-written by Andrew Ward and Natan Ponieman The race is continually heating up in the psychedelics space. An array of companies, educational institutions and investors have already obtained patents on formulations, processes, compounds and other aspects of psychedelics treatment.

Psychecelics Company Atai Life Sciences Files For Nasdaq Listing In Sector's Highly Anticipated IPO

Atai Life Sciences could soon become the second psychedelics company to list on a major U.S. exchange. The Berlin-based biotech firm filed Tuesday with the SEC to raise $100 million in an IPO using the ticker symbol "ATAI."

Psyched: Entheon Launches Psychedelics Genetic Test, Mydecine Unveils Psychedelic Drug Candidates, California Bill Passes Senate Committee

Entheon Biomedical Corp. announced the launch of a psychedelics genetic test kit last week through its wholly owned subsidiary HaluGen Life Sciences Inc.

Psyched: Novamind Partners With Merck, Atai Expands To Japan, Australia Funds Psychedelics Research

Novamind Strikes Research Deal With Merck

Psyched: The Patents Dilemma, Compass 2020 Earnings, New Psilocybin Bill In NY

These days, the psychedelics finds itself in the midst of a public debate around the moral implications of patents and intellectual property for certain medicines and treatments.

Psyched: Atai Raises $157M, Silo Wellness Goes Public, Mydecine Completes Export Of 'Magic Mushrooms'

Atai Inks Largest Fundraise In Sector History With $157M Series D Psychedelics and mental health company Atai Life Sciences has raised $157 million in venture capital.

Psychedelics Startup Atai Inks Largest Fundraise In Sector History With $157M Series D

Psychedelics and mental health company Atai Life Sciences has raised $157 million in venture capital. The Series D funding round is being touted as the psychedelics sector’s largest to date.

Psyched: First Psychedelics ETF Debuts; Hawaii, Florida and Connecticut Eye Psilocybin Legalization; Psyence Goes Public

First Psychedelics ETF Debuts On NEO Exchange Psychedelics’ first exchange traded fund went public last Wednesday.

Atai Partners With Harvard's Massachusetts General Hospital For Psychedelics Research

Atai Life Sciences t announced on Tuesday a new research collaboration with Massachusetts General Hospital, the largest teaching hospital of Harvard Medical School.

Psyched: Compass Launches Center Of Excellence, Entheon Purchases HaluGen, Atai Buys Majority Stake In Recognify

Compass Launches Center Of Excellence Compass Pathways (NASDAQ: CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland.

Psyched: MindMed Launches DTx Division, ATAI Closes $125M Series C, Novamind Raises CA$10M

Novamind Raises CA$10M, Heads Towards CSE Listing Toronto-based psychedelics company Novamind Ventures announced the closing of a private placement for CA$10 million ($7.6 million).

Psyched: Compass Joins Nasdaq, Field Trip Goes Public, MindMed Begins Trials, ATAI Launches MDMA Subsidiary

Compass Pathways Files for an IPO at NASDAQ UK-based Compass Pathways wants to become the first psychedelics company to list on a major U.S. stock exchange. The psilocybin research company intends to make its initial public offering (IPO) through NASDAQ under the ticker symbol CMPS.

ATAI Launches Subsidiary To Develop MDMA Derivatives

Psychedelics and biotech company ATAI Life Sciences announced on Monday the launch of a new subsidiary that will focus on the development of MDMA derivatives for the treatment of post-traumatic stress disorder and other indications. EmpathBio will be a wholly owned subsidiary of ATAI, led by CEO Glenn Short.

'Psyched': Atai Launches DMT Subsidiary, NeuroPharm Collaborates With Dutch University

ATAI Launches Subsidiary Focused on DMT

ATAI Launches Subsidiary Focused On Active Ingredient In Hallucinogenic Brews

Psychedelics and biotech company ATAI Life Sciences announced Wednesday the launch of Viridia Life Sciences. This wholly-owned subsidiary will be dedicated to the study and production of the DMT molecule (N,N-Dimethyltryptamine).

'Psyched': Atai Buys Kures, Beckley Psytech Raises $3.7M, Mydecine Acquires NeuroPharma

PSYCHED is now weekly! As the psychedelics industry grows, so does the need for news. For this reason, our column covering the most important developments in medicinal psychedelics is now a weekly feature.